Skin Metastases In Small-Cell Lung Cancer (SCLC). Frequency, Associations, response To Treatment And Prognosis

2010 ◽  
Author(s):  
Ioannis Dimitroulis ◽  
Kyriaki Tsikritsaki ◽  
Georgios Zarbis ◽  
Katerina Dimakou ◽  
Michalis Toumbis
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Response To Treatment ◽  
Small Cell Lung ◽  
Skin Metastases

scholarly journals Targeting KRAS in Non-Small Cell Lung Cancer

2022 ◽  
Vol 11 ◽  
Author(s):  
Elena Corral de la Fuente ◽  
Maria Eugenia Olmedo Garcia ◽  
Ana Gomez Rueda ◽  
Yolanda Lage ◽  
Pilar Garrido
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Response To Treatment ◽  
Small Cell Lung ◽  
Area Of Interest ◽  
Therapy Strategies ◽  
Effective Drugs

Kirsten Rat Sarcoma viral oncogene homolog (KRAS) is the most frequently altered oncogene in Non-Small Cell Lung Cancer (NSCLC). KRAS mutant tumors constitute a heterogeneous group of diseases, different from other oncogene-derived tumors in terms of biology and response to treatment, which hinders the development of effective drugs against KRAS. Therefore, for decades, despite enormous efforts invested in the development of drugs aimed at inhibiting KRAS or its signaling pathways, KRAS was considered to be undruggable. Recently, the discovery of a new pocket under the effector binding switch II region of KRAS G12C has allowed the development of direct KRAS inhibitors such as sotorasib, the first FDA-approved drug targeting KRAS G12C, or adagrasib, initiating a new exciting era. However, treatment with targeted KRAS G12C inhibitors also leads to resistance, and understanding the possible mechanisms of resistance and which drugs could be useful to overcome it is key. Among others, KRAS G12C (ON) tricomplex inhibitors and different combination therapy strategies are being analyzed in clinical trials. Another area of interest is the potential role of co-mutations in treatment selection, particularly immunotherapy. The best first-line strategy remains to be determined and, due to the heterogeneity of KRAS, is likely to be based on combination therapies.

scholarly journals CD8+ PD-1+ T-cells and PD-L1+ circulating tumor cells in chemotherapy-naïve non-small cell lung cancer: towards their clinical relevance?

2019 ◽  
Vol 11 ◽  
pp. 175883591985319 ◽  
Author(s):  
Athanasios Kotsakis ◽  
Galatea Kallergi ◽  
Despoina Aggouraki ◽  
Zaharoula Lyristi ◽  
Filippos Koinis ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Circulating Tumor Cells ◽  
Cell Lung Cancer ◽  
Clinical Relevance ◽  
Small Cell ◽  
Response To Treatment ◽  
Small Cell Lung

Background: Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there is a correlation between the levels of PD-1+ and PD-L1+-expressing immune cells (ICs) and circulating tumor cells (CTCs) in patients with non-small cell lung cancer (NSCLC). Patients and methods: Peripheral blood was obtained from 37 chemotherapy-naïve patients with metastatic NSCLC before treatment. PD-1 and PD-L1 expression was evaluated (1) on ICs with anti-tumor function (CD4+ and CD8+ T-cells, B-cells, monocytes/dendritic cells) using flow cytometry, (2) on CTCs by immunofluorescence and (3) on cells from tumor tissues by immunohistochemistry. The levels of PD-1+ and PD-L1+-expressing ICs were correlated with progression-free survival (PFS). Results: The presence of PD-1+ CD8+ cells, with reduced interferon (IFN)-γ expression, but not other ICs, were positively correlated with PD-L1+ CTCs ( p < 0.04). Increased percentages of PD-1+ CD8+ T-cells, were associated with a worse response to treatment ( p = 0.032) and shorter PFS ( p = 0.023) which, in multivariate analysis, was revealed as an independent predictor for decreased PFS [hazard ratio (HR): 4.1, p = 0.0007]. Conclusion: The results of the current study, for first time, provide evidence for a possible interaction between ICs and CTCs in NSCLC patients via the PD-1/PD-L1 axis and strongly support that the levels of PD-1+ CD8+ in these patients may be of clinical relevance.

Flow cytometric analysis of tumor DNA profile related to response to treatment and survival in small-cell lung cancer

1997 ◽  
Vol 14 (1) ◽  
pp. 35-38 ◽  
Author(s):  
Markku M. T. Virén ◽  
Antti T. Ojala ◽  
Vesa V. Kataja ◽  
Jorma J. Mattila ◽  
Pasi A. Koivisto ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Flow Cytometric Analysis ◽  
Small Cell ◽  
Response To Treatment ◽  
Small Cell Lung ◽  
Dna Profile ◽  
Flow Cytometric ◽  
Tumor Dna

scholarly journals Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252537
Author(s):  
Konstantinos Rounis ◽  
Dimitrios Makrakis ◽  
Chara Papadaki ◽  
Alexia Monastirioti ◽  
Lambros Vamvakas ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Liver Metastases ◽  
Small Cell Lung Cancer ◽  
Bone Metastases ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Response To Treatment ◽  
Single Individual ◽  
Small Cell Lung ◽  
Neutrophil Lymphocyte Ratio

Objective We prospectively recorded clinical and laboratory parameters from patients with metastatic non-small cell lung cancer (NSCLC) treated with 2nd line PD-1/PD-L1 inhibitors in order to address their effect on treatment outcomes. Materials and methods Clinicopathological information (age, performance status, smoking, body mass index, histology, organs with metastases), use and duration of proton pump inhibitors, steroids and antibiotics (ATB) and laboratory values [neutrophil/lymphocyte ratio, LDH, albumin] were prospectively collected. Steroid administration was defined as the use of > 10 mg prednisone equivalent for ≥ 10 days. Prolonged ATB administration was defined as ATB ≥ 14 days 30 days before or within the first 3 months of treatment. JADBio, a machine learning pipeline was applied for further multivariate analysis. Results Data from 66 pts with non-oncogenic driven metastatic NSCLC were analyzed; 15.2% experienced partial response (PR), 34.8% stable disease (SD) and 50% progressive disease (PD). Median overall survival (OS) was 6.77 months. ATB administration did not affect patient OS [HR = 1.35 (CI: 0.761–2.406, p = 0.304)], however, prolonged ATBs [HR = 2.95 (CI: 1.62–5.36, p = 0.0001)] and the presence of bone metastases [HR = 1.89 (CI: 1.02–3.51, p = 0.049)] independently predicted for shorter survival. Prolonged ATB administration, bone metastases, liver metastases and BMI < 25 kg/m2 were selected by JADbio as the important features that were associated with increased probability of developing disease progression as response to treatment. The resulting algorithm that was created was able to predict the probability of disease stabilization (PR or SD) in a single individual with an AUC = 0.806 [95% CI:0.714–0.889]. Conclusions Our results demonstrate an adverse effect of prolonged ATBs on response and survival and underscore their importance along with the presence of bone metastases, liver metastases and low BMI in the individual prediction of outcomes in patients treated with immunotherapy.

Patterns of metastasis, response to treatment and survival in young patients with advanced non small cell lung cancer (NSCLC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 7343-7343
Author(s):  
A. Addeo ◽  
V. Dongiovanni ◽  
N. Birocco ◽  
D. Dongiovanni ◽  
C. Fissore ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Young Patients ◽  
Small Cell ◽  
Response To Treatment ◽  
Small Cell Lung
Sign in / Sign up

Export Citation Format

Share Document